Ghent University Academic Bibliography

Advanced

Fluoroenzymeimmunoassay to detect systemic sclerosis-associated antibodies: diagnostic performance and correlation with conventional techniques

Carolien Bonroy UGent, Vanessa Smith UGent, Katleen Van Steendam UGent, JENS VAN PRAET UGent, Dieter Deforce UGent, Katrien Devreese UGent and Filip De Keyser UGent (2012) CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 30(5). p.748-755
abstract
Objective : Detection of systemic sclerosis-associated antibodies (SSc-Ab) in routine clinical practice is mostly restricted to anti-centromere and anti-Scl-70 antibodies. However, also other antinuclear antibodies have been shown to be valuable diagnostic and prognostic markers for the disease. The aim of this study was to evaluate the diagnostic performance of measuring the most prevalent SSc-Ab with fluoroenzymeimmunoassay (FEIA) as an alternative for the combined conventional techniques (CCT). Methods : Sera from 144 consecutive systemic sclerosis (SSc) patients previously tested by CCT (indirect immunofluorescence on HEp-2000, western blotting, protein radio immunoprecipitation and a well-documented line immunoassay) and an additional group of 266 disease controls (80 rheumatoid arthritis, 58 systemic lupus erythematosus, 50 spondyloarthropathy, 48 osteoarthritis, 18 polymyalgia rheumatica and 12 ANCA-associated vasculitis) were retrospectively evaluated. Anti-centromere-B, anti-Scl-70, anti-RNA polymerase III and anti-PM/Scl antibodies were measured using FEIA. Results : Using cut-off values corresponding with. likelihood ratios larger than 10 FEIA obtained the following sensitivities: 45.1% for anti-centromere-B, 15.3% for anti-Scl-70, 5.6% for anti-RNA polymerase III and 2.1% for anti-PM/Scl. The overall agreement between combined conventional techniques and FEIA was good for all individual reactivities (kappa>0.800). The overall diagnostic sensitivity of 68.1% and diagnostic specificity of 98.1% were comparable to those obtained by CCT. Conclusion : FEIA testing for anti-centromere-B, anti-Scl-70, anti-RNA polymerase III and anti-PM/Scl-100 shows good performance and represents an accurate alternative for the time-consuming combined conventional techniques.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
systemic sclerosis, fluoroenzymeimmunoassay, extractable nuclear antigen, Antinuclear antibodies, LUPUS-ERYTHEMATOSUS, ANTINUCLEAR ANTIBODIES, CLINICAL ASSOCIATIONS, REVISED CRITERIA, B ANTIBODIES, AUTOANTIBODIES, SCLERODERMA, RNA-POLYMERASE-III, LINKED-IMMUNOSORBENT-ASSAY, RHEUMATOID-ARTHRITIS
journal title
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
Clin. Exp. Rheumatol.
volume
30
issue
5
pages
748 - 755
Web of Science type
Article
Web of Science id
000310828600016
JCR category
RHEUMATOLOGY
JCR impact factor
2.655 (2012)
JCR rank
14/29 (2012)
JCR quartile
2 (2012)
ISSN
0392-856X
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
2965234
handle
http://hdl.handle.net/1854/LU-2965234
alternative location
http://www.clinexprheumatol.org/abstract.asp?a=5216
date created
2012-07-30 13:44:44
date last changed
2013-01-16 11:53:52
@article{2965234,
  abstract     = {Objective : Detection of systemic sclerosis-associated antibodies (SSc-Ab) in routine clinical practice is mostly restricted to anti-centromere and anti-Scl-70 antibodies. However, also other antinuclear antibodies have been shown to be valuable diagnostic and prognostic markers for the disease. The aim of this study was to evaluate the diagnostic performance of measuring the most prevalent SSc-Ab with fluoroenzymeimmunoassay (FEIA) as an alternative for the combined conventional techniques (CCT). 
Methods : Sera from 144 consecutive systemic sclerosis (SSc) patients previously tested by CCT (indirect immunofluorescence on HEp-2000, western blotting, protein radio immunoprecipitation and a well-documented line immunoassay) and an additional group of 266 disease controls (80 rheumatoid arthritis, 58 systemic lupus erythematosus, 50 spondyloarthropathy, 48 osteoarthritis, 18 polymyalgia rheumatica and 12 ANCA-associated vasculitis) were retrospectively evaluated. Anti-centromere-B, anti-Scl-70, anti-RNA polymerase III and anti-PM/Scl antibodies were measured using FEIA. 
Results : Using cut-off values corresponding with. likelihood ratios larger than 10 FEIA obtained the following sensitivities: 45.1\% for anti-centromere-B, 15.3\% for anti-Scl-70, 5.6\% for anti-RNA polymerase III and 2.1\% for anti-PM/Scl. The overall agreement between combined conventional techniques and FEIA was good for all individual reactivities (kappa{\textrangle}0.800). The overall diagnostic sensitivity of 68.1\% and diagnostic specificity of 98.1\% were comparable to those obtained by CCT. 
Conclusion : FEIA testing for anti-centromere-B, anti-Scl-70, anti-RNA polymerase III and anti-PM/Scl-100 shows good performance and represents an accurate alternative for the time-consuming combined conventional techniques.},
  author       = {Bonroy, Carolien and Smith, Vanessa and Van Steendam, Katleen and VAN PRAET, JENS and Deforce, Dieter and Devreese, Katrien and De Keyser, Filip},
  issn         = {0392-856X},
  journal      = {CLINICAL AND EXPERIMENTAL RHEUMATOLOGY},
  keyword      = {systemic sclerosis,fluoroenzymeimmunoassay,extractable nuclear antigen,Antinuclear antibodies,LUPUS-ERYTHEMATOSUS,ANTINUCLEAR ANTIBODIES,CLINICAL ASSOCIATIONS,REVISED CRITERIA,B ANTIBODIES,AUTOANTIBODIES,SCLERODERMA,RNA-POLYMERASE-III,LINKED-IMMUNOSORBENT-ASSAY,RHEUMATOID-ARTHRITIS},
  language     = {eng},
  number       = {5},
  pages        = {748--755},
  title        = {Fluoroenzymeimmunoassay to detect systemic sclerosis-associated antibodies: diagnostic performance and correlation with conventional techniques},
  url          = {http://www.clinexprheumatol.org/abstract.asp?a=5216},
  volume       = {30},
  year         = {2012},
}

Chicago
Bonroy, Carolien, VANESSA SMITH, Katleen Van Steendam, JENS VAN PRAET, Dieter Deforce, Katrien Devreese, and Filip De Keyser. 2012. “Fluoroenzymeimmunoassay to Detect Systemic Sclerosis-associated Antibodies: Diagnostic Performance and Correlation with Conventional Techniques.” Clinical and Experimental Rheumatology 30 (5): 748–755.
APA
Bonroy, C., SMITH, V., Van Steendam, K., VAN PRAET, J., Deforce, D., Devreese, K., & De Keyser, F. (2012). Fluoroenzymeimmunoassay to detect systemic sclerosis-associated antibodies: diagnostic performance and correlation with conventional techniques. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 30(5), 748–755.
Vancouver
1.
Bonroy C, SMITH V, Van Steendam K, VAN PRAET J, Deforce D, Devreese K, et al. Fluoroenzymeimmunoassay to detect systemic sclerosis-associated antibodies: diagnostic performance and correlation with conventional techniques. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2012;30(5):748–55.
MLA
Bonroy, Carolien, VANESSA SMITH, Katleen Van Steendam, et al. “Fluoroenzymeimmunoassay to Detect Systemic Sclerosis-associated Antibodies: Diagnostic Performance and Correlation with Conventional Techniques.” CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 30.5 (2012): 748–755. Print.